Yosemite led a $120m Round in Solve Therapeutics.

Yosemite, an oncology-focused venture fund investing in biotech and healthcare innovations, led a $120m Round in Solve Therapeutics, a developing novel antibody-drug conjugates engineered for selectivity and optimized payload delivery, as well as novel patient-selection diagnostics, with participation from Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, Merck & Co., SymBiosis, Alexandria Venture Investments, AyurMaya Capital Management, General Atlantic, and Surveyor Capital. “We’re thrilled to partner with an outstanding syndicate of investors who share our vision for developing best-in-class ADCs. Since founding the company, we’ve built a differentiated platform that combines next-generation ADC engineering, a superior hydrophilic linker system, and novel patient-selection diagnostics. This investment syndicate represents a strong endorsement of our science, our team, and our mission to develop more effective and safer targeted therapies for patients with solid tumors,” Dave Johnson, Solve Therapeutics CEO & Co-Founder.